Live Markets, Charts & Financial News

Medicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually

3

aprott/iStock via Getty Images

Novo Nordisk’s (NVO) weight-loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries with obesity and cardiovascular disease, could cost the system up to $145 billion a year.

If all eligible beneficiaries receive Wegovy

Comments are closed, but trackbacks and pingbacks are open.